Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Correction

Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni, Majid Safa

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Excerpt

The original article [1] incorrectly states that OMO-1 is a MYC inhibitor in two instances: in the Direct MYC Inhibition sub-section of the MYC Inhibitors section, and in Table 3. …
Literature
1.
Metadata
Title
Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Authors
Seyed Esmaeil Ahmadi
Samira Rahimi
Bahman Zarandi
Rouzbeh Chegeni
Majid Safa
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01152-9

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Review

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Review

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Review

Third-line therapy for chronic myeloid leukemia: current status and future directions

Research

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Review

Prostate cancer and PARP inhibitors: progress and challenges

Review

Metabolic landscapes in sarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits